Does Metformin Benefit The Risk And Survival Of Lung Cancer In T2DM Patients?

1. Huateng Pharma https://en.huatengsci.com/ Does Metformin Benefit The Risk And Survival Of Lung Cancer In T2DM Patients? Metformin, marketed under the trade name Glucophage, is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. Metformin is a biguanide antihyperglycemic agent. It works by decreasing glucose production by the liver, by increasing the insulin sensitivity of body tissues, and by exerting an anorexiant effect, thereby reducing caloric intake. The results of a newly published meta-analysis study showed that metformin may reduce the risk of lung cancer in patients with type 2 diabetes by 22%, and in Asian populations this value can reached to 34%. In addition, for patients with type 2 diabetes who have already suffered from lung cancer, metformin can increase the survival rate of patients by 35% significantly. Metformin is the first-line drug for the treatment of type 2 diabetes (T2DM) and it has been widely used in clinical practice. Tumor proliferation and progression are increased in patients with cancer complicated with T2DM due to increased levels of hyperinsulinemia, hyperglycemia, and inflammatory cytokines. In recent years, studies have found that metformin has a certain anti-cancer effect. Does metformin benefit the risk and survival of lung cancer in T2DM patients?

2. Huateng Pharma https://en.huatengsci.com/ Current studies believe that metformin plays an anticancer role mainly by activating AMPK and inhibiting protein synthesis. In clinical practice, it has been found that in patients with ovarian cancer with T2DM, taking metformin after diagnosis is associated with improved overall survival and progression-free survival. Similar results have been found in studies of colorectal cancer. However, it was found that taking metformin had no significant effect in prostate cancer or breast cancer. The relationship between metformin and the prevalence and survival rate of lung cancer is controversial. To explore this issue, Chinese researchers conducted a meta-analysis on the "The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: A meta‐analysis", and the results of the study were published in the journal Clinical Pharmacy and Therapeutics. Metformin can reduce lung cancer risk in patients with T2DM by 22% In the meta-analysis of all eight studies, T2DM patients treated with metformin had a 22% reduction in lung cancer risk compared with T2DM patients treated without metformin (HR=0.78，95%CI 0.70-0.86；P＜0.00001). Picture 1 research result In 4 studies of Asian patients, it was observed that metformin had a significant preventive effect on lung cancer (HR=0.66, 95%CI 0.56-0.76; P<0.00001), but this significant effect was not observed in the four European patients (HR=0.90, 95%CI 0.78-1.03; P=0.12) (Table 1). Table 1 Effect of metformin on the risk of lung cancer in patients with T2DM in Asia/Europe

3. Huateng Pharma Metformin can increase lung cancer survival rate in patients with T2DM by 35% https://en.huatengsci.com/ In the analysis of all 10 studies, metformin use was significantly associated with a 35% increase in overall survival in lung cancer patients (HR=0.65, 95%CI 0.55-0.77;P < 0.00001). Picture 2 research result In 5 studies on Asian patients (HR=0.57, 95%CI 0.49-0.66;P < 0.00001) and 5 studies on non-Asian patients (HR=0.79, 95%CI 0.71-0.88;In P < 0.0001), metformin was observed to significantly improve the survival rate of lung cancer in T2DM patients. In the histology of lung cancer, there is also a significant correlation between the use of metformin and the survival rate. In 7 studies on patients with non-small cell lung cancer (NSCLC) (HR=0.68, 95%CI 0.54-0.84; P=0.0004) and 2 studies on patients with small cell lung cancer (SCLC) (HR=0.52, 95%) In CI 0.39-0.69; P<0.00001), the metformin group showed significant benefits (Table 2). Table 2 Effect of metformin on the survival in patients with T2DM lung cancer The results of this study showed that metformin could reduce the risk of lung cancer in patients with T2DM and improve the survival rate. Its protective effect on Asian patients was clear. This study has some implications for the clinical treatment of patients with T2DM with lung cancer.

4. Huateng Pharma https://en.huatengsci.com/ T2DM, formerly known as adult-onset diabetes, is a form of diabetes that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Besides metformin, semaglutide and liraglutide are two common drugs which also used to treat type 2 diabetes. Huateng Pharma, a leading pharmaceutical company focusing on R&D of pharmaceutical intermediates, we provide Anti-Diabetic intermediates such as semaglutide intermediates and liraglutide intermediates with high purity. Reference: [1] The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: A meta‐analysis [2] Metformin improves survival in lung cancer patients receiving EGFR-TKIs therapy Related articles: [1] The things you need to know about diabetes [2] Novo Nordisk's Semaglutide Shows Promise in Weight Loss [3] Semaglutide : First Oral GLP-1 Treatment for Type 2 Diabetes [4] Antidiabetic Drugs Classification and Mechanism of Action